Direct-to-store model (delivering drugs directly to each retailer’s stores) of distributors are increasingly becoming more popular among retailers (represents 93% of sales in 2017, up from 74% in 2007 ...

Drug distributor McKesson missed estimates for third-quarter revenue on Wednesday, hurt by less-than-expected sales in its ...

With a positive outlook, McKesson raised its fiscal 2025 adjusted EPS guidance to a range of $32.55 to $32.95, indicating ...

Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors ...

Cardinal's pharmaceutical and specialty solutions segment distributes branded, generic, and specialty drugs and over-the-counter healthcare and consumer products. Cardinal plays a central role in the ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

McKesson's strategic growth in oncology, biopharma and tech drives momentum in 2025. Can MCK overcome its sustaining challenges with robust finances and innovation?

In a report released today, Allen Lutz from Bank of America Securities maintained a Buy rating on McKesson (MCK – Research Report). The ...

In a report released yesterday, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on McKesson (MCK – Research Report), with a ...

Investors should watch how McKesson navigates competitive and regulatory pressure. Notable competitors like Cardinal Health could challenge McKesson's market position. Upcoming quarters may see ...

S&P Global Ratings has revised its outlook on McKesson Corp (NYSE:MCK). to positive from stable, while affirming its 'BBB+' ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.